Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Andrei C. Sposito; Otávio Berwanger; Luiz Sérgio F. de Carvalho; José Francisco Kerr Saraiva

doi:10.1186/s12933-019-0825-1

Cardiovascular Diabetology (Mar 2019)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Andrei C. Sposito,
Otávio Berwanger,
Luiz Sérgio F. de Carvalho,
José Francisco Kerr Saraiva

Affiliations

Andrei C. Sposito: Atherosclerosis and Vascular Biology Laboratory (AtheroLab), Cardiology Division, Faculty of Medical Sciences, State University of Campinas (Unicamp)
Otávio Berwanger: Academic Research Organization (ARO), Albert Einstein Hospital
Luiz Sérgio F. de Carvalho: Atherosclerosis and Vascular Biology Laboratory (AtheroLab), Cardiology Division, Faculty of Medical Sciences, State University of Campinas (Unicamp)
José Francisco Kerr Saraiva: Cardiology Division, Pontifical Catholic University of Campinas Medicine School

DOI: https://doi.org/10.1186/s12933-019-0825-1
Journal volume & issue: Vol. 18, no. 1
pp. 1 – 3

Abstract

Read online

Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular outcomes.

Published in Cardiovascular Diabetology

ISSN: 1475-2840 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://cardiab.biomedcentral.com/

About the journal